


REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP03/0823 into the U.S. National Phase of prosecution. In the specification, an Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Claims 12, 13, 15 and 16 have been cancelled. Claims 3-9 have been amended to eliminate multiple dependencies and to put the claim set in the proper U.S. format. Entry of this amendment into the record is requested.

Respectfully submitted,



Chris P. Miller
Attorney for Applicants
Registration No. 55,852

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5629
Facsimile (610) 270-5090
N:\cpm\cases\p32976\preliminary amendment.doc

ABSTRACT OF THE DISCLOSURE

Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.